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Background. Hepatitis C virus (HCV) coinfection among people with human immunodeficiency virus (HIV) might perturb 
immune function and HIV persistence. We aimed to evaluate the impact of HCV clearance with direct-acting antivirals (DAAs) on 
immune activation and HIV persistence in HIV/HCV-coinfected individuals on antiretroviral therapy (ART).
Methods. In a prospective observational study, ART-treated participants with HIV/HCV coinfection received sofosbuvir/
daclatasvir ± ribavirin (n = 19). Blood samples were collected before DAA therapy, at the end of treatment, and 12 months after 
DAA termination (12MPT). T- and natural killer (NK)-cell phenotype, soluble plasma factors, cell-associated (CA)-HIV deoxyri-
bonucleic acid (DNA) forms (total, integrated, 2LTR), CA-unspliced (US) and multiple-spliced ribonucleic acid (RNA), and plasma 
HIV RNA were evaluated.
Results. Hepatitis C virus clearance was associated with (1) a downmodulation of activation and exhaustion markers in CD4+, 
CD8+ T, and NK cells together with (2) decreased plasma levels of Interferon gamma-induced protein 10 (IP10), interleukin-8 (IL-
8), soluble (s)CD163 and soluble intercellular adhesion molecule (sICAM). Cell-associated US HIV RNA was significantly higher at 
12MPT compared to baseline, with no change in HIV DNA or plasma RNA.
Conclusions. Elimination of HCV in HIV/HCV-coinfected individuals alters immune function and the transcriptional activity 
of latently infected cells. This report provides insights into the effects of HCV coinfection in HIV persistence and regards coinfected 
subjects as a population in which HIV remission might prove to be more challenging.
Keywords.  direct antiviral agents; hepatitis C; HIV reservoir; immune activation.
Antiretroviral therapy (ART) quickly and persistently sup-
presses viral replication resulting in improved quality of life for 
people with human immunodeficiency virus/acquired immune 
deficiency syndrome (PWHA), reduced AIDS-associated death 
rates, reduced morbidity events, and increased life expectancy 
[1]. However, treatment is life-long with several limitations [2]. 
If treatment is interrupted, plasma viral load (VL) rapidly re-
bounds, due to the persistence of long-lived and proliferating 
latently infected cells that persist on ART [3, 4].
Because of overlapping pathways of transmission between 
HIV and hepatitis C virus (HCV), approximately 2 to 5 mil-
lion individuals worldwide are estimated to be coinfected 
[5, 6]. In Argentina, coinfected individuals represent approx-
imately 20% of PWHA [7]. Hepatitis C virus direct antiviral 
agents (DAAs), which target specific steps of HCV replication 
cycle, represent a major development in the treatment of HCV, 
with the possibility of >95% of cure and low rate of adverse 
events, even with advanced or decompensated cirrhosis [8]. 
The DAA-mediated clearance of HCV is associated with loss 
of intrahepatic immune activation by interferon (IFN)-α, re-
covery of T-cell proliferation, normalization of natural killer 
(NK)-cell phenotype and function [9], and restoration of 
type I IFN response both in acute [10] and chronic [11] HCV 
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infection, as well as enhanced HCV-specific CD8+ T-cell re-
sponses [12].
Understanding the interaction between HCV coinfection 
before and after clearance of HCV on the HIV reservoir is im-
portant, because HIV/HCV coinfection is common and the 
high cure rate after DAAs allows for the opportunity to as-
sess the impact of HCV on HIV persistence. Hepatitis C virus/
HIV coinfection has been associated with increased levels 
of immune activation compared with HIV monoinfection 
including higher levels of microbial products [13, 14], low 
levels of detectable plasma HIV in PWHA on ART [15, 16], 
and increased risk of HIV virological failure [17]. Early re-
ports showed that cell-associated (CA) HIV ribonucleic acid 
(RNA) levels decreased after HCV treatment with IFN-α plus 
ribavirin (RBV) [18], whereas no effect [18] or a decrease [19, 
20] was observed in HIV DNA. More recent studies have re-
ported an increase in CD4+ T cells harboring integrated HIV 
deoxyribonucleic acid (DNA) in HIV/HCV even after spon-
taneous HCV clearance [21], whereas DAA-mediated HCV 
clearance was associated with stable or increased levels of HIV 
CA DNA [22, 23].
We hypothesized that the elimination of HCV coinfection 
with DAAs would modulate the size and/or transcriptional ac-
tivity of the HIV reservoir due to the restoration of HCV-driven 
immune dysregulation. We quantified the immediate and 
long-term effects of DAA-mediated HCV clearance in HIV/
HCV-coinfected participants on multiple markers of immune 
function and on HIV persistence in blood. Overall, we observed 
a downmodulation of NK- and T-cell activation markers as well 
as of soluble plasma activation markers after treatment with 
DAAs. This was accompanied by an increase in peripheral CA 
HIV unspliced (US)-RNA with no change in HIV DNA. These 
results suggest a relationship between HCV and transcriptional 
activity of the HIV reservoir.
METHODS
This was a longitudinal, single-center study approved by the 
local Ethics Committee of the Huésped Foundation (Buenos 
Aires, Argentina). All participants were included after signing 
the informed consent from March 17, 2016 to May 12, 2016, 
and samples were analyzed during 2017, 2018, and 2019. 
Sample sizes were determined using the Harris, Horvitz, and 
Mood method to provide 80% power, at the 5% level of sig-
nificance. Peripheral blood from 19 ART-treated participants 
with HIV/HCV coinfection were collected at baseline (BSL) be-
fore the start of DAA, at the end of treatment (EOT) (either at 
completion of 12 or 24 weeks of DAA), and after 12 months of 
DAA termination (12MPT). At 12MPT, samples from 2 partici-
pants were not available due to lung cancer diagnosis and loss of 
follow up, respectively. All individuals received HCV treatment 
with sofosbuvir (SOF) and daclatasvir (DCV), and 12 partici-
pants also received ribavirin (RBV). Diagnosis of liver cirrhosis 
was made by liver biopsy or hepatic transient elastography 
(>14 kPa). No participants had signs of hepatic decompensa-
tion at the time of enrollment. Sustained virological response 
(SVR) to DAA was defined by nondetectable HCV RNA (lower 
limit of detection, 12 IU/mL) at 12 weeks after EOT. Hepatitis 
C virus RNA was also evaluated at 48 weeks after EOT and it 
was nondetectable in all cases. Inclusion criteria were successful 
ART with HIV VL <40 copies/mL for more than 24  months. 
Peripheral blood mononuclear cells (PBMCs) were obtained 
from 60  mL whole blood by Ficoll-Hypaque density gradient 
centrifugation (GE Healthcare, UK) and cryopreserved in 
liquid nitrogen.
Cell-associated HIV RNA (US and multiple-spliced [MS]) 
and DNA forms (total HIV, HIV-integrated, and 2LTR circles) 
were evaluated in sorted CD4+ T cells by quantitative real-time 
polymerase chain reaction (PCR), as described previously [24]. 
Ultrasensitive HIV plasma VL was evaluated in all samples by 
replicate testing using the Aptima HIV-1 quant assay (Hologic). 
T-cell and NK-cell phenotyping was performed by flow 
cytometry. Soluble plasma factors were quantified by enzyme-
linked immunosorbent assay. Detailed methods are described 
in Supplementary Material S1.
Statistical analyses were performed using GraphPad Prism 7 
(GraphPad Software) and InfoStat (UNC, Cordoba, Argentina) 
and R project (R Foundation for Statistical Computing, Vienna, 
Austria) softwares. Data were analyzed using nonparametric 
methods. Longitudinal association between CA US-HIV RNA 
and plasma RNA was estimated by using a generalized linear 
mixed-effects regression model. Correlation analyses were per-
formed using Spearman’s rank test. For the phenotypic analyses, 
SPICE 6.0 software (https://niaid.github.io/spice/) was used 
following the experimental and technical considerations pub-
lished by the software developers [25]. All tests were considered 
significant when P < .05.
RESULTS
Study Group
A total of 19 HIV/HCV-coinfected individuals were enrolled. 
Most participants were male (74%), and the median age was 
49  years (interquartile range, 46–53). All participants were 
receiving ART with at least 2  years of documented undetect-
able HIV VL. During DAA, all individuals received integrase 
inhibitor-based ART. Sofosbuvir/DCV with RBV was pre-
scribed for 12 weeks in 9 participants and 24 weeks in 3 par-
ticipants, and 7 participants received SOF/DCV for 24 weeks 
without RBV. The use of RBV depended on HCV genotype and 
drug tolerance. All participants achieved SVR. Further clinical 
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Human Immunodeficiency Virus Persistence After Direct-Acting Antiviral 
Treatment
We quantified the frequency and transcriptional activity of 
HIV-infected cells before (BSL sample) and after DAA treat-
ment (EOT and 12MPT samples) as an indicator of HIV per-
sistence. No statistically significant differences were observed in 
CA viral DNA (total, integrated, and 2LTR circles) (Figure 1A), 
ie, overall levels remained stable from BSL to 12MPT. No dif-
ferences in plasma HIV RNA, measured by ultrasensitive sin-
gle-copy assay, were found among time points (Figure 1B).
Levels of CA MS-RNA remained low and stable along all the 
studied time points (Figure 1B). However, a statistically significant 
increase in CA US-RNA was observed between BSL and 12MPT 
(P = 0.0203) (Figure  1B). Of note, the higher increments in 
US-RNA were observed in those participants who did not receive 
RBV within their regimens (Supplementary Figure S1); US-RNA 
was higher at BSL in the RBV group, nevertheless no differences 
in any of the clinical or laboratory parameters were observed be-
tween both groups that could account for that disparity.
To provide further insight into the transcriptional activity 
of the infected cells, the ratio of CA US-RNA and both the 
integrated and total HIV DNA were calculated. In addition, 
the ratio between CA MS- and US-RNA was obtained to es-
timate the relative efficiency of transcriptional elongation and 
splicing. No differences were found among BSL, EOT, and 
12MPT (Figure  1C). Finally, we hypothesized that increased 
US-RNA, if associated with increased viral transcription, would 
be correlated with plasma RNA. The longitudinal study of CA 
US-HIV RNA and plasma RNA across all 3 time points evalu-
ated depicted a potential association between both variables 
(P = 0.002) (Figure 2).
T-Cell Immune Phenotyping
The profile of different memory subsets and the expression 
of different markers were studied on CD8+ and CD4+ T cells 
(gating strategy is shown in Supplementary Figure S2). We 
defined 6 CD8+ or CD4+ T-cell subpopulations: naive (TNaive, 
CCR7+CD45RO−CD28+CD95−), stem memory (TSCM, CCR
Table 1. Subjects Characteristics
Characteristics BSL n = 19 EOT n = 19 12MPT n = 17 P Valuea,b
Age (years)c 49 (46–53) -- 49 (45–52) --
Male sex (n, %)d 14 (73.4) -- 13 (76.4) --
CD4 count (cells/μL)c 291 (231–776) 460 (205–692) 506 (233–1058) >.999/.455
CD8 count (cells/μL)c 849 (498–1263) 917 (407–1293) 1041 (503–1389) .851/.216
NK cells (%)c 8.9 (5.6–16.2) 8.1 (5.7–39.6) 9.5 (4.2–28.2) .903/.845
CD4/CD8 ratioc 0.56 (0.33–0.78) 0.52 (0.39–0.78) 0.51 (0.39–0.71) .025/.397
Time of HCV infection (years)c 13 (11–22) -- -- --
Time of HIV infection (years)c 19 (12–21) -- -- --
HCV viral load (log10 copies)
c 5.89 (5.56–6.13) All <1.3 All <1.3 <.001/<.001
Time of ARV (years)c 10.5 (4–16.5) -- -- --
Routes of Transmission (n, %)d     
 IDU 14 (73.7) -- -- --
 Heterosexual 5 (21.1) -- -- --
 MSM 1 (5.3) -- -- --
HCV Genotype (n, %)d     
 1a 12 (63.2) -- -- --
 1b 1 (5.3) -- -- --
 1 3 (15.8) -- -- --
 3 3 (15.8) -- -- --
Liver stiffness (kPa)c 22.2 (17.9–32.2) ND ND --
APRI scorec 1.16 (0.58–2.09) 0.76 (0.29–0.84) 0.55 (0.29–1.03) .0084/.0004
ALT (IU/L)c 67.5 (46–82) 27 (17–49) 33 (24–49) <.001/<.001
AST (IU/L)c 78.5 (68.2–93.7) 33 (26–45) 38 (32–51) <.001/<.001
Albumin (g/dL)c 4.2 (3.6–4.5) 4.2 (3.9–4.4) 4.4 (4.1–4.5) .382/.020
Platelets (×103/mm3)c 111 (98–213) 121 (87–229) 121 (77–193) .922/.130
Total bilirubin (μg/dL)c 0.85 (0.72–1.1) 0.80 (0.55–1.42) 0.80 (0.70–1.0) .183/.450
Prothrombin time (%)c 74 (63–93) 71 (63–81) 76 (69–85) .531/.867
Abbreviations: 12MPT, 12 month post treatment; ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio; ARV, antiretroviral therapy; AST, aspartate transaminase; 
BSL, baseline; EOT, end of treatment; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injecting drug user; MSM, men who have sex with men; ND, not determined; NK, 
natural killer.
aBSL vs EOT, Wilcoxon test. 
bBSL vs 12MPT, Wilcoxon test.
cMedian (interquartile range).
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7+CD45RO−CD28+CD95+), central memory (TCM, CCR7
+
CD45RO+CD28+CD95+), transitional memory (TTM, CCR
7−CD45RO+CD28+CD95+), effector memory (TEM, CCR
7−CD45RO+CD28−CD95+), and terminal effector (TTE, 
CCR7−CD45RO−CD28−CD95+) cells. The distribution of these 
subsets was analyzed as previously described [26]. The memory 
profile within the CD4+ T-cell compartment showed the fol-
lowing hierarchical distribution: TTM cells represented the 
highest proportions, followed by TCM, TNaive, TEM, TSCM, and TTE 
cells (Supplementary Figure S3A). Regarding the CD8+ T-cell 
compartment, the distribution was as follows: TEM cells com-
prised the highest proportions, followed by TTE, TTM, TNaive, TCM, 
and TSCM cells (Supplementary Figure S3B). Memory distribu-
tion observed on both T-cell compartments were conserved 
across the 3 time points analyzed (BSL, EOT, and 12MPT), and 
no significant differences were observed between them.
We next quantified the expression of immune surface 
markers (such as CD38, HLA-DR, CD127, PD-1, and CD25) 
in both T-cell compartments. At BSL, elevated proportions 































































































































































































































Figure 1. Human immunodeficiency virus (HIV) reservoir dynamics in HIV/hepatitis C virus-coinfected individuals treated with direct-acting antivirals (DAA). Cell-associated 
(CA) HIV deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), as well as plasma HIV RNA were evaluated in coinfected individuals before treatment initiation (baseline 
[BSL]), at the end of treatment (EOT), and 12 months after finalizing DAA therapy (12MPT). The CA total HIV DNA, integrated DNA and 2LTR (A), CA multiple-spliced (MS)-
RNA, unspliced (US)-RNA, and plasma RNA (B), and US-RNA/integrated DNA, US-RNA/total HIV DNA, and MS/US-RNA ratios (C) are shown. Viral DNA and RNA copies 
were calculated relative to 106 cell equivalents (CE). Individual values, median and 25th and 75th percentiles, are indicated. Statistical comparisons were performed using 
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and CD4+/CD38+/HLA-DR+/PD-1+ T cells were observed. 
These proportions were significantly reduced by 12MPT 
(Supplementary Figure S4A). The decay in activation markers 
observed from BSL to 12MPT was observed in all CD4+ T-cell 
subpopulations, with CD4+ TTM and TEM having the largest and 
most significant changes.
A similar scenario was observed on CD8+ T cells. At BSL, 
higher proportions of CD8+ T cells expressing CD38 and 
HLA-DR were recorded. After DAA treatment, the expres-
sion of these activation markers was significantly reduced. 
The proportions of double-positive CD8+/CD38+/HLA-DR+ 
and triple-positive CD8+/CD38+/HLA-DR+/PD-1+ T cells 
were significantly reduced at EOT and 12MPT, respectively 
(Supplementary Figure S5A). Similar to the CD4+ T-cell 
compartment, the decay in CD38, HLA-DR, and PD-1 ex-
pression was observed in all CD8+ T-cell subpopulations 
(Supplementary Figure S5B). In this compartment, the 
subpopulations that exhibited more pronounced modifica-
tions after HCV clearance were the more differentiated pheno-
types (CD8+ TTM, TEM, and TTE).
Natural Killer Cell Immune Phenotyping
Compared with BSL, CD38 expression on NK cells was sig-
nificantly reduced at EOT, and it continued at this lower level 
throughout the study (Supplementary Figure S6A). The fre-
quency of HLA-DR-expressing NK cells was significantly re-
duced at EOT (Supplementary Figure S5B), whereas there was 
a slight increase by 12MPT levels, but it still remained at lower 
levels than those from BSL (Supplementary Figure S6B). When 
analyzing the distribution of NK-cell subsets defined by the ex-
pression of both HLA-DR and CD38, we found a significant re-
duction in the frequency of HLA-DR+/CD38+ NK cells, with a 
concomitant increase in the frequency of cells negative for both 
markers at EOT and 12MPT (Supplementary Figure S6C). In 
addition, the apoptosis-inducing receptor CD95 was studied. 
Percentages of CD95-expressing cells at EOT were lower than 
those from BSL; however, CD95 levels rebounded at 12MPT, 
reaching similar levels observed at BSL (Supplementary Figure 
S6D). Moreover, a trend towards a decreased frequency of 
both CD25+ and CD69+ NK cells at EOT and 12MPT was ob-
served; however, neither CD25 nor CD69 expression differed 
among time points (Supplementary Figure S6E and F). It is 
interesting that, similar to our previous results, the frequency 
of CD25+/CD69+/CD95+ NK cells was reduced at EOT and 
12MPT, whereas percentages of triple-negative NK cells were 
significantly augmented (Supplementary Figure S6G). Finally, 
expression of NK cell-activating receptor NKG2D and natural 
cytotoxic receptors (NCRs) NKp30 and NKp46 were evalu-
ated. As shown in Supplementary Figure S5H, the percentage 
of NKG2D-expressing NK cells was significantly decreased at 
EOT, compared with BSL. When relative fluorescence inten-
sities (RFIs) were examined, a significant reduction in NKG2D 
expression was also obtained at 12MPT (Supplementary 
Figure S6H, right panel). Regarding NCRs, although NKp46 
expression was not differentially modulated, we observed a 
trend towards a reduction in the expression of NKp30 at EOT 
and 12MPT. No differences were found when analyzing RFI 
(Figure 6H).
Soluble Factors
Then, plasma concentrations of different soluble factors, fre-
quently associated with markers of immune activation and in-
flammation, were evaluated. Interleukin (IL)-17 and IL-1β were 
below the limit of detection so they could not be quantified. For 
IL-6, IL-2, soluble (s)CD14, IFN-γ, tumor necrosis factor-α, and 
sCD23, no differences were observed along the different time 
points evaluated (Supplementary Figure S7A−F). In contrast, 
IFN-inducible protein 10 (IP-10), IL-8 soluble intercellular ad-
hesion molecule 1 (sICAM-1), and sCD163 were elevated at BSL 
but were significantly reduced at EOT (P < 0.0001, P = 0.0015, 
P < 0.0001, and P = 0.0002, respectively) and remained low (al-
ways compared with BSL) at 12MPT (P = 0.0107, P = 0.0426, 
P = 0.0001, and P = 0.002, respectively) (Supplementary Figure 
S7G−J).
Association Between Immune Status and Human Immunodeficiency Virus 
Persistence
Finally, we assessed the relationship between the different im-
mune parameters and HIV viral persistence. All immune meas-


























Figure 2. Association analysis between cell-associated (CA) unspliced (US) 
and plasma human immunodeficiency virus (HIV) ribonucleic acid (RNA) in HIV/
hepatitis C virus-coinfected individuals treated with direct-acting antivirals 
(DAA). The CA US-RNA as well as plasma HIV RNA were evaluated in coinfected 
individuals before treatment initiation (baseline [BSL]), at the end of treatment 
(EOT), and 12 months after finalizing DAA therapy (12MPT). Relationship between 
variables was measured by applying a generalized linear mixed-effects model 
with plasma RNA as the independent variable and CA US-RNA and time as fixed-
effect predictors; P value for the CA US-RNA coefficient is shown. White, gray, 
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evaluated at 12MPT were compared with US-RNA levels 
at 12MPT, the US-RNA fold-up between 12MPT and BSL 
(12MPT/BSL), and the US-RNA change (delta) between 12MPT 
and BSL (12MPT-BSL). For simplicity, results are shown in heat 
maps denoting r values. Significant correlations are highlighted, 
and the corresponding y versus x plot is shown. No statisti-
cally significant correlations were found between US-RNA at 
12MPT, US-RNA fold-increase, or delta US-RNA with param-
eters evaluated on CD4+ or NK cells (data not shown). In con-
trast, US-RNA fold-increase was negatively associated with the 
proportions of CD8 TTM cells and positively associated with 
%CD8 TEM cells (Figure 3A). Levels of most cytokines at 12MPT 
showed positive r values with the 3 virological parameters 
evaluated; however, only sCD163 showed a statistically signif-
icant correlation with delta US-RNA (Figure 3B).
DISCUSSION
Human immunodeficiency virus remission and cure clinical re-
search has largely occurred in high-income settings where (1) 
most participants are men who have sex with men, (2) subtype 
B is the most prevalent viral variant, (3) malnutrition is not a 
regular finding, and (4) there is a low burden of coinfections. 
All of these factors may be important determinants of the size 
and transcriptional activity of the HIV reservoir, and cure strat-
egies may need to be different for high- and low-middle income 
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Figure 3. Correlation analyses between cellular and soluble markers of immune activation and inflammation, and human immunodeficiency virus (HIV) reservoirs in HIV/
hepatitis C virus-coinfected individuals treated with direct-acting antivirals (DAA). Heat map representation of Spearman rank correlation coefficients computed for the ex-
pression of CD8+ T-cell immune markers at 12 months after finalizing DAA therapy (12MPT) (A) and plasma levels of soluble factors of immune activation and inflammation at 
12MPT (B) versus HIV unspliced (US)-ribonucleic acid (RNA) at 12MPT (US-RNA 12 MPT), US-RNA fold up between 12MPT and baseline (BSL) (Fold-up US-RNA 12MPT/BSL), 
and differences between US-RNA at 12MPT minus levels at BSL (Delta US-RNA 12MPT-BSL). The colors denote both the correlation direction and strength of association, 
ranging from −1 (blue) to 1 (red). Statistical significant associations are further shown below each panel in individual × vs y plots. Spermans’s r and P values are shown. ICAM, 
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in immune function [27]. In this study, we found that DAA-
mediated HCV clearance in HIV/HCV-coinfected subjects 
is associated with the following: a clear improvement in liver 
functionality and a tendency to improved CD4+ T cells counts; 
a decrease in the surface expression of activation and exhaus-
tion markers in CD4+ and CD8+ T cells and in NK cells; lower 
plasma levels of IP-10 and IL-8 and indicators of macrophage 
and monocyte activation, such as sCD163 and sICAM; and 
higher levels of US-RNA at 12 months post-DAA treatment.
Therapies with DAAs are very effective oral and short-
term treatments, with more than 90% of SVR, even in HIV-
coinfected individuals [28]. This has been reflected in our study, 
where all participants achieved viral clearance and improved 
liver function parameters, despite the presence of advanced he-
patic disease. In addition, a recovery in both CD4+ and CD8+ 
T-cell phenotype (in terms of the expression of activation and 
exhaustion markers) was registered after DAA treatment. These 
findings are in line with previous reports after DAA for HIV/
HCV coinfection describing improved HCV-specific CD8+ 
T-cell functionality and lower PD-1 expression, recovery of 
the CD4+ T-cell compartment, and a replenishment of T cells 
with memory/effector phenotype [29–31]. Likewise, a decrease 
in the proportion of activated NK cells was found after DAA 
treatment, in agreement with previous publications describing 
reduced expression of activation markers and cytolytic activity 
[9, 29, 31, 32]. Although others have observed an increase in 
NK cell frequency after DAA treatment [33–37], this was not 
found in our study. It might be because in this study, all individ-
uals presented with end-stage liver fibrosis, which is linked to 
low NK cell frequencies [34]. In these individuals, liver damage 
could be a stronger factor modifying NK-cell population than 
HCV clearance. Finally, lower levels of soluble inflammatory 
factors, such as IP-10, were previously reported [38] and recap-
itulated in our study.
The first reports regarding the impact of HCV on HIV per-
sistence on ART, described that IFN-α/RBV treatment was as-
sociated with decreased levels of total and integrated HIV DNA 
in CD4+ T cells [20] and 2LTR circles from PBMCs [19]—as 
assessed by reverse-transcription PCR—and also CD4+ T-cell 
HIV RNA reduction [18]. In this latter report, no differences 
were found regarding CD4+ T-cell proviral HIV DNA, 2LTR 
circles, and replication-competent reservoirs measured with 
quantitative viral outgrowth assay (qVOA). Nevertheless, it is 
important to highlight that those therapies were based on 2 
drugs (IFN-α and RBV) that could also have a direct effect on 
HIV replication [39, 40]. More recently, 3 studies have evalu-
ated the levels of CA HIV DNA in PBMCs before and after 
DAAs for HCV treatment. Parisi et al [22] described that there 
was an increase or decrease in total HIV DNA after DAA treat-
ment depending on the magnitude of HIV viremia (low-level 
versus undetectable) before starting DAAs. In other works, HIV 
DNA remained stable before and after DAA treatment [23, 41]. 
All 3 forms of HIV DNA measured here (total, integrated, and 
2LTR) remained stable during follow up. The differential find-
ings might be explained by the use of purified CD4+ T cells in-
stead of total PBMCs to quantify HIV DNA and a more rigorous 
criteria regarding HIV undetectable VL before enrollment. It is 
also worth noting that, although extensively used, PCR-based 
techniques for measuring both total and integrated HIV DNA 
face considerable limitations, because they tend to overestimate 
the size of the reservoir due to the high prevalence of defective 
proviruses. Thus, these results should not be interpreted as if 
there was no effect on the size of the competent reservoir [42].
We also studied the transcriptional activity of infected cells by 
measuring US-RNA and MS-RNA and plasma RNA. A signifi-
cant increase in US-RNA was found 12 months after HCV clear-
ance with no increase in CA MS-RNA or plasma RNA levels. 
Correlation analysis indicated that the elevation of US-RNA was 
accompanied by diminished proportions of CD8+ TTM cells and 
higher proportions of CD8+ TEM cells. This could be an indicator 
that higher transcription might be accompanied by production 
of at least some viral proteins that might be priming memory 
CD8+ T-cell responses. On the other hand, the steady state of 
MS-RNA and plasma RNA levels could be reflecting a block in 
viral cycle termination. This raises different hypotheses. Higher 
levels of US-RNA might represent higher rates of genuine HIV 
transcripts but also host-HIV read-through transcripts [43, 44]. 
However, these latter transcripts have been shown to contribute 
poorly to the bulk of HIV RNA, so this hypothesis seems un-
likely [44]. Yukl et  al [43] showed that nonactivated latently 
infected CD4+ T cells show substantial transcription initiation 
that is subsequently blocked at the elongation, polyadenylation, 
and splicing steps. In addition, evidence indicates that unstimu-
lated naive and memory CD4+ T-cell subsets support transcrip-
tion initiation and elongation with different capacity; however, 
upon stimulation, TEM cells are the cell subset that more effi-
ciently achieves transcript elongation [45]. Although we did 
not observe differences in the bulk distribution of CD4+ T-cell 
subsets from BSL to 12MPT, we cannot exclude modifications 
within particular T helper subsets that might justify the higher 
frequency of US-RNA-positive cells in periphery. The potential 
variations in T helper subsets could contribute to our findings 
as a consequence of increased transcription initiation, en-
hanced blockade, or even reduced trafficking of these cells to 
the tissues secondary to the changes of chemokines and che-
mokine receptors expression after HCV clearance. Moreover, 
HCV has been shown to replicate in lymphocytes [46], thus 
HCV elimination might modify signaling pathways leading to 
increased HIV transcription in these cells. Finally, it has been 
demonstrated that DAA-mediated viral clearance was accom-
panied by a lower activity of type I  IFN (α, γ, β) receptors, 
meaning a downregulation of IFN-stimulated genes, in HCV-
monoinfected individuals [11]. This might impact the tran-
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showed that, in vitro, once latency is stablished, IFN-α could 
act as a reversal agent promoting viral replication [47]. A priori, 
this result is in contrast with our findings. However, it should 
be noted that the establishment and maintenance of latency is a 
complex multifactorial phenomenon governed by mixed, some-
times opposed, mechanisms, and the net result of this is what is 
observed ex vivo.
CONCLUSIONS
This work opens new perspectives that should be addressed. 
First, we used PCR-based techniques to measure viral reservoirs. 
These assays tend to overestimate the frequency of replication 
competent virus, because both defective and nondefective viral 
strains are detected. The aim of future studies should include 
assays aimed at identifying the translation-competent reser-
voir [48] as well as qVOA, TILDA (Tat/rev Induced Limiting 
Dilution Assay), and IPDA (intact proviral DNA assay) assays 
to address this limitation [49, 50]. Second, longer time of follow 
up would provide more information regarding the long-term 
effect of HCV clearance in HIV transcriptional activity. In addi-
tion, it would be relevant to evaluate the magnitude and quality 
of HIV-specific immune response after HCV clearance and its 
association with HIV persistence, because it could be hypothe-
sized that the increase in HIV transcriptional activity might be 
associated with a boosting of HIV-specific T cells. Third, all 
of the individuals included in the present study presented ad-
vanced liver fibrosis; it will be important to evaluate whether 
the results found are reproducible in a cohort of participants 
with low to mild liver fibrosis. Finally, results could not be ex-
tended to the intrahepatic CD4+ T cells, but a similar or higher 
increase in HIV transcription is expected. There is certain evi-
dence to suggest that hepatocytes and hepatic stellate cells sup-
port HIV infection [51]. Thus, the modification in the liver 
environment, including decreased HCV-specific immune sur-
veillance, could lead to a relapse in HIV transcription in these 
cells. Nevertheless, results presented here provide an important 
insight into the effects of chronic HCV infection on virus per-
sistence, confirming HCV coinfection as a relevant factor im-
posing an extra challenge in HIV remission studies, even after 
HCV clearance.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
corresponding author.
Supplementary file 1. Detailed description of methods used in this 
manuscript.
Supplementary figure S1. Cell-associated (CA) HIV US-RNA dynamics 
in HIV/HCV-coinfected individuals treated with DAA with or without 
ribavirin. Cell-associated HIV unspliced (US)-RNA was evaluated in 
coinfected individuals receiving DAA or DAA plus ribavirin (RBV), before 
treatment initiation (baseline [BSL]), at the end of treatment (EOT), and 
12 months after finalizing therapy (12MPT). Viral DNA and RNA copies 
were calculated relative to 106 cell equivalents (CE). Individual values, me-
dian and 25th and 75th percentiles, are indicated. Statistical comparisons 
were performed using Wilcoxon test; *, P ˂ 0.05.
Supplementary figure S2. Gating strategy used for the identification of 
the studied cellular populations, by flow cytometry. To study immune phe-
notype of both NK and T cells, initial gating was performed on a forward 
scatter area (FSC-A) versus FSC-height (FSC-H) plot to remove doub-
lets. Dead cells were then excluded on the bases of Zombie NIR fluores-
cence. Then, lymphocytes were selected in FSC versus side scatter (SSC) 
plot. Subsequently, CD3 expression was analyzed in a CD3 versus SSC-H 
dot plot (A). For NK analysis, CD3 and CD56 expression was analyzed on 
total lymphocytes. CD3−/CD56+ cells were selected. Then, expression of 
cellular markers of activation was studied. Representative flow cytometry 
plots for Nkp46, NKp30, NKG2D, CD69, and CD95 are shown (B). For 
identification of CD4+ and CD8+ T-cells, a CD8 versus CD4 dot plot was 
constructed. Expression of CD25, CD38, HLA-DR, CD127, and PD-1 on 
CD8+ cells is shown from 1 representative subject (C, top panel). To an-
alyze the distribution of the different phenotype subsets on CD8+ T cells, 
CD45RO versus CCR7 dot plots were constructed and shown in C (bottom 
panel). Subsequently, CD28 and CD95 were used to define on (1) CCR7+/
CD45RO− gate, naive and stem cell memory (SCM) T-cells, (2) CCR7+/
CD45RO+ gate, central memory T cells, (3) CCR7−/CD45RO+ gate,  tran-
sitional memory (TM) and effector memory T cells (EM), and (4) CCR7−/
CD45RO− gate,  terminal effector T cells (TE). Identical analysis was per-
formed on the CD4+ T-cell subset (data not shown ).
Supplementary figure S3. Distribution of memory subpopulations within 
CD4+ and CD8+ T-cells from HIV/HCV-coinfected individuals treated with 
DAA. Proportion of naive cells; stem cell memory (SCM), central memory 
(CM), transitional memory (TM), effector memory (EM), and terminal ef-
fector (TE) T cells were evaluated in CD4+ (A) or CD8+ T-cells (B) from 
coinfected individuals at baseline (BSL), end of treatment (EOT), and 
12 months after finalizing DAA therapy (12MPT). The analyses were per-
formed with SPICE software. In bar graphs, the color code shown at the 
bottom mirrors the one shown in the pies. Each dot represent individual 
values, boxes extend from 25th to 75th percentiles, and lines within boxes 
represent the median value.
Supplementary figure S4. Immune marker expression in CD4+ T cells 
from HIV/HCV-coinfected individuals treated with DAA. Modulation of 
immune cell markers was evaluated before DAA therapy initiation (base-
line [BSL]), at the end of treatment (EOT), and 12 months after finalizing 
DAA therapy (12MPT). Frequencies of CD38, HLA-DR, PD-1, CD38/
HLA-DR, and CD38/HLA-DR/PD-1 positive CD4+ T cells are shown. 
CD25 and CD127 expression were also monitored, but no differences were 
found and thus no results are shown. (A). Analysis of distribution of CD4+ 
T-cell populations in terms of memory subsets was performed with SPICE 
software (B). Individual values are indicated. Boxes represent the IQR of 
25–75, and horizontal lines within boxes represent the medians. P values 
were calculated using the Wilcoxon test. Asterisks denote different P values: 
*, P ˂ 0.05; **, P ˂ 0.01.
Supplementary figure S5. Immune marker expression in CD8+ T cells 
from HIV/HCV-coinfected individuals treated with DAA. Modulation of 
immune cell markers was evaluated before DAA therapy initiation (base-
line [BSL]), end of treatment (EOT), and 12 months after finalizing DAA 
therapy (12MPT). Frequencies of CD38, HLA-DR, CD38/HLA-DR, and 
CD38/HLA-DR/PD-1 positive CD8+ T cells are shown. CD25 and CD127 
expression were also monitored, but no differences were found and thus 
no results are shown. (A). Analysis of distribution of CD8+ T-cell popula-
tions in terms of memory subsets was performed with SPICE software (B). 
Individual values are indicated. Boxes represent the IQR of 25–75, and hor-
izontal lines within boxes represent the medians. P values were calculated 
using the Wilcoxon test. Asterisks denote different P values: *, P ˂ 0.05; **, 
P ˂ 0.01; ***, P ˂ 0.001.
Supplementary figure S6. Study of NK cell activation in HIV/HCV-
coinfected individuals treated with DAA therapy. NK cell immune profile 
was assessed in coinfected individuals at BSL, EOT, and 12MPT. Frequencies 
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Nkp30, and NKp46 positive NK cells (H) are shown. Analysis of distribu-
tion of NK cells subsets in terms of HLA-DR/CD38 (C) and CD25/CD69/
CD95 expression (G) was performed with SPICE software. Relative fluores-
cence intensity (RFI) for NKG2D, Nkp30, and NKp46 stains on NK cells 
(H, right panel) are shown. Individual values are indicated. Boxes represent 
the IQR of 25–75, and horizontal lines within boxes represent the medians. 
P values were calculated using Wilcoxon test. Asterisks denote different P 
values: *, P ˂ 0.05; ** P ˂ 0.01; ***, P ˂ 0.001.
Supplementary figure S7. Evaluation of soluble markers of immune acti-
vation and inflammation in HIV/HCV-coinfected individuals treated with 
DAA therapy. Plasma from coinfected individuals was evaluated before 
DAA therapy initiation (baseline [BSL]), at the end of treatment (EOT), 
and after 12 months of DAA therapy finalization (12MPT). Plasma IL-6 (A), 
IL-2 (B), sCD14 (C), TNF-α (D), IFN-γ (E), sCD23 (F), IP-10 (G), IL-8 (H), 
sICAM (I), and sCD163 (J) levels are indicated. Boxes represent the IQR 
of 25–75, whiskers extend from minimum to maximum, and horizontal 
lines within boxes represent the medians. P values were calculated using 
Wilcoxon test. Asterisks denote different P values: *, P ˂ 0.05; **, P ˂ 0.01; 
***, P ˂ 0.001.
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